NCT06780033 is a Phase 1 clinical trial of ART-101 - SAD in Hypertension, sponsored by Arnatar Therapeutics, Inc..

Who is sponsoring NCT06780033?

NCT06780033 is sponsored by Arnatar Therapeutics, Inc..

What drugs are being tested in NCT06780033?

Interventions in NCT06780033: ART-101 - SAD, Placebo.

What condition does NCT06780033 study?

NCT06780033 studies Hypertension.

Is NCT06780033 still recruiting?

NCT06780033 is currently terminated. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT06780033

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate ART101 in Adult Participants With Hypertension

Terminated Phase 1 Last updated 22 September 2025

What this trial tests

Phase 1 trial testing ART-101 - SAD in Hypertension in 1 participant. Terminated before completion.

Timeline

17 March 2025

Primary endpoint
30 April 2025

30 April 2025

Quick facts

Lead sponsor	Arnatar Therapeutics, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1
Start date	17 March 2025
Primary completion	30 April 2025
Estimated completion	30 April 2025
Sites	3 locations across Australia

Drugs / interventions tested

ART-101 - SAD — full drug profile →
Placebo

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

Arnatar Therapeutics, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, Pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of ART101 administered via subcutaneous injection to hypertensive adult participants. An anticipated 5 dose cohorts (one as optional) with maximum of 40 participants will be randomized in SAD study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other Arnatar Therapeutics, Inc. trials

Trials by the same sponsor.

NCT07529600 — A Phase I Clinical Study of ART101 Injection in Healthy Adult Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06780033 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arnatar Therapeutics, Inc.
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06780033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing